Press releases

Opinions, ideas, and research from NPLB

ICER’s ‘updated’ methodology falls far short

ICER acknowledges that their math is flawed, but they don't fix their mistakes.

NPLB Statement on ICER’s Flawed Value Assessment Framework

ICER math must be significantly updated to incorporate quantifiable patient & societal benefits

NPLB Submits Comments on Medicare Drug Price Negotiation Program to CMS

Read NPLB's proposed fixes for successful IRA implementation

NPLB Submits Small Biotech Exception Comments to CMS

IRA's time-limited small biotech "exception" will not work as intended

New NPLB Video Illustrates Why Patients Deserve Better Math to Value New Drugs

Insurance companies harm patients by not taking into account the true value of medicines.

One Thousand Investors, Researchers, Patients, & Innovators Sign Letter Urging Critical Fixes to Senate Rx Bill

NPLB released a coalition letter urging fixes to the Senate Reconciliation Drug bill.

“Abbie” Video Highlights Need for Insurance Reforms that Lower Out-of-Pocket Costs

If a doctor prescribes a treatment and the insurer authorizes it, the copay should be affordable.

Lawmakers Urged to Support Biopharma Innovation and Affordability

Pass reforms to lower out-of-pocket costs. Caution! Price controls could cease biopharma investment

NPLB Gets Animated: Roadmap to Patient Affordability and Innovation

Animation: Insurance Reform Needed to Cover Prescribed Medicines at Low Cost

When Simpler isn't Better

A case for generalizing cost-effectiveness math to avoid undervaluing medicines

CMS Rule to Lower Maximum Out-of-Pocket Costs by $400 Will Help Patients, More Reductions Needed

NPLB welcomed key provisions in CMS Notice of Benefit and Payment Parameters for 2022 Final Rule

NPLB Applauds Growing Momentum for Insurance Reforms that Lower Out-of-Pocket Costs for Patients

Prioritizing reforms such as drug pricing and access that help patients is essential.

Patient Out-of-Pocket Costs Continue to Climb While Insurers are Covering Fewer Drugs

Despite Reductions in Pharmaceutical Manufacturer Net Drug Prices

NPLB Applauds President’s Expansion of Affordable Healthcare

More Americans Helped, More Still to be Done

How To Kill The Conversation That Makes Innovation Possible

A short analysis

Interested in getting in touch?

Contact a member of our staff

Feel free to reach out with questions, concerns, or comments.

Contact us